NKGN.OTC.PinkNkgen Biotech, INC
10-Q: NKGen Biotech Reports Q3 2024 Results, Navigates Financial Challenges
Sentiment:
Quarterly Report
NKGen Biotech's Q3 2024 results reveal a complex financial landscape marked by a net income of $6.6 million alongside ongoing efforts to secure additional funding and address going concern uncertainties.
Delay expectedThe company was not able to file its quarterly report on Form 10-Q for the period ended September 30, 2024 with the SEC within the time period specified by the Exchange Act.
Capital raiseThe company plans to continue to fund its losses from operations and capital funding needs through additional debt or equity financings to be received from related parties, private equity, or other sources.The company is seeking opportunities for raising additional funds through potential alternatives, which may include, among other things, the issuance of equity, equity-linked, and/or debt securities, debt financings, forward purchase arrangements or other capital sources.
Worse than expectedThe company has expressed substantial doubt about its ability to continue as a going concern.The company's revolving line of credit is past due, and the company is in the process of amending the agreement with the parties to allow for a further extension or over-time repayment under specific terms.
Summary
- NKGen Biotech reported a net income of $6.6 million for Q3 2024, a significant improvement compared to the $33.2 million net loss in Q3 2023.
- For the nine months ended September 30, 2024, the company's net loss was $14.9 million, compared to a $49.3 million net loss for the same period in 2023.
- Research and development expenses decreased to $2.8 million in Q3 2024 from $3.9 million in Q3 2023, and to $9.1 million for the nine months ended September 30, 2024 from $11.6 million for the same period in 2023.
- General and administrative expenses increased to $4.0 million in Q3 2024 from $3.0 million in Q3 2023, and to $12.8 million for the nine months ended September 30, 2024 from $8.7 million for the same period in 2023.
- The company is actively pursuing additional debt or equity financing to fund operations and address its going concern uncertainty.
- As of February 28, 2025, there were 44,947,588 shares of common stock issued and outstanding.
- The company's revolving line of credit is past due, and the company is in the process of amending the agreement with the parties to allow for a further extension or over-time repayment under specific terms.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there's a net income for Q3, the going concern warning, past due debt, and need for further capital raises raise significant concerns.
Positives
- The company achieved net income in Q3 2024, a significant improvement from the previous year.
- Research and development expenses decreased, indicating improved efficiency or strategic prioritization.
- The company is actively working to secure additional financing to support its operations.
Negatives
- The company has a significant accumulated deficit of $177.0 million as of September 30, 2024.
- The company has expressed substantial doubt about its ability to continue as a going concern.
- The company's revolving line of credit is past due, and the company is in the process of amending the agreement with the parties to allow for a further extension or over-time repayment under specific terms.
Risks
- The company's ability to raise financing in the future is uncertain.
- The company's ability to service its operations and expenses and other liquidity needs and to address its ability to continue as a going concern is uncertain.
- The company's success in retaining or recruiting, or changes required in, our officers, key employees or directors after the Business Combination is uncertain.
- The company's ability to successfully commercialize any product candidates that it successfully develops and that are approved by applicable regulatory authorities is uncertain.
- The company's expectations for the timing and results of data from clinical trials and regulatory approval applications are uncertain.
- Unfavorable conditions in the company's industry, the global economy or global supply chain, including financial and credit market fluctuations, international trade relations, pandemics, political turmoil, natural catastrophes, warfare, and terrorist attacks could negatively impact the company.
Future Outlook
The company intends to advance the clinical development of SNK01 and continue enrolling the Phase I/IIa trial in the United States and Canada for AD, and (ii) complete the Phase I trial with SNK02 in refractory solid tumors. We also intend to conduct a trial in PD, to evaluate the expansion into other neurodegenerative diseases, accelerate development in oncology through strategic collaborations, and continue investment in our manufacturing technology.
Industry Context
The company operates in the competitive biotechnology industry, focusing on NK cell therapies for neurodegenerative diseases and cancer, which are areas of significant unmet medical need and ongoing research.
Comparison to Industry Standards
- It is difficult to compare NKGen Biotech's results directly to industry standards due to its unique focus on SNK cell therapies and its stage of development.
- Comparable companies in the cell therapy space include companies such as Fate Therapeutics, Atara Biotherapeutics, and Nkarta Therapeutics, but their specific technologies and clinical programs differ.
- Industry benchmarks for clinical trial success rates and commercialization costs vary widely depending on the therapeutic area and regulatory pathway.
Legal Proceedings
- The company is subject to legal proceedings and claims, which arise in the ordinary course of business.
- The company is currently defending against a claim from a former employee alleging wrongful termination and whistleblower retaliation.
Related Party Transactions
- The company has entered into exclusive license agreements with NKMAX, as amended in October 2021, April 2023 and August 2023, pursuant to which the Company acquired certain intellectual property for the development of treatments for cancer, neurodegenerative diseases, and other fields of use.
- For the three and nine months ended September 30, 2024, the Company recorded $0.1 million of research and development expenses associated with the purchase of laboratory supplies from NKMAX.
- The company's related party financial instruments include (i) the Founder Shares, including Deferred Founder Shares described above in this Note 8, (ii) the SPA Warrants described in Note 5, Warrants , (iii) the Working Capital Warrants described in Note 5, Warrants , (iv ) the Senior Convertible Notes described in Note 6, Convertible Notes , (v) 2024 Related Party Convertible Bridge Loan described in Note 6, Convertible Notes, (vi) Related Party Convertible Bridge Notes described in Note 6, Convertible Notes, (vii) select Legacy Convertible Notes described in Note 6, Convertible Notes , (viii) the Related Party Loans described in Note 7, Debt , (ix) the Private Warrants described in Note 5, Warrants , (x) 400,000 of the Convertible Bridge Warrants described in Note 5, Warrants , and (xi) 550,000 of the Convertible 2024 Note Warrants described in Note 5, Warrants .
Stakeholder Impact
- Shareholders face potential dilution from future equity offerings.
- Employees may be affected by cost-cutting measures, including potential layoffs.
- Customers (patients) may benefit from successful clinical trials and potential new therapies.
- Suppliers and creditors face risks associated with the company's going concern uncertainty.
Next Steps
- Continue enrolling the Phase I/IIa trial in the United States and Canada for AD.
- Complete the Phase I trial with SNK02 in refractory solid tumors.
- Conduct a trial in PD.
- Evaluate the expansion into other neurodegenerative diseases.
- Accelerate development in oncology through strategic collaborations.
- Continue investment in our manufacturing technology.
Key Dates
| Date | Description |
|---|---|
| 2018-02 | Company entered into an operating lease agreement for office space located in 10 Pasteur, Irvine, California. |
| 2019-11 | From November to December 2019, the Company issued convertible promissory notes for aggregate proceeds of $17.3 million. |
| 2020-09-17 | Company entered into a strategic collaboration with Affimed GmbH. |
| 2021-01-28 | Graf Acquisition Corp. IV was originally incorporated in Delaware. |
| 2021-10 | Company entered into an operating lease agreement for office space located in 19700 Fairchild, Irvine, California. |
| 2022-10-14 | Company received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for SNK02 allogeneic NK cell therapy for solid tumors. |
| 2023-03 | From March to September 2023, the Company issued convertible promissory notes for aggregate proceeds of $17.3 million. |
| 2023-04-14 | Company entered into the Agreement and Plan of Merger by and among Graf, Austria Merger Sub, Inc., and NKGen Biotech, Inc. |
| 2023-06 | The study associated with the strategic collaboration with Affimed was discontinued by mutual agreement. |
| 2023-06 | Company entered into a $5.0 million revolving line of credit agreement. |
| 2023-09-29 | Consummation of the transactions under the Merger Agreement. |
| 2023-10-02 | Common stock and warrants of the combined company began trading on The Nasdaq Stock Market LLC under the symbols NKGN and NKGNW, respectively. |
| 2023-10-20 | Company received IND clearance from the FDA for SNK01 in AD. |
| 2023-10-25 | NKGen presented its Phase I clinical trial data at the 16th Annual Clinical Trials on Alzheimers Disease conference. |
| 2023-11-09 | Company entered into a new operating lease agreement for office space located in Irvine, California. |
| 2023-12-21 | Company received the No Objection Letter from Health Canada for our clinical trial application of SNK01 in AD. |
| 2023-12-26 | Company and an FPA Investor entered into an amendment to their Forward Purchase Agreement. |
| 2023-12-28 | Company dosed our first participant in the US on the SNK01-AD01 clinical trial. |
| 2024-01 | From January to February 2024, the Company and certain FPA Investors entered into several additional amendments to the Forward Purchase Agreements. |
| 2024-02-09 | Company amended their Warrant Subscription Agreement with a Warrant Investor. |
| 2024-04-05 | Agreement was amended to extend the maturity date of the revolving line of credit to September 18, 2024. |
| 2024-04-18 | Company amended their Forward Purchase Agreement with an FPA Investor. |
| 2024-04-25 | Company amended their Warrant Subscription Agreements with Warrant Investors. |
| 2024-04-26 | Company received IND clearance from the FDA for SNK01 in PD. |
| 2024-05-20 | SNK01 was cleared by an Internal Review Board (IRB) to enter into the Phase 2 portion of the clinical trial. |
| 2024-07 | From July to September 2024, the Company and certain FPA Investors entered into several additional amendments to the Forward Purchase Agreements. |
| 2024-08-07 | NKGen issued 2,083,333 shares of NKGen common stock and 2,750,000 warrants to an accredited investor. |
| 2024-08-26 | NKGen entered into a Securities Purchase Agreement with an accredited investor. |
| 2024-09-09 | 2,000,000 share warrants were exercised, resulting in the issuance of 2,000,000 common shares. |
| 2024-09-16 | Conversion prices of the Notes and the exercise prices of the Warrants with an original price of $2.00 per share, have been reset to the adjusted price of $0.60 per share. |
| 2024-09-18 | The agreement was amended to extend the maturity date of the revolving line of credit to September 18, 2024. |
| 2024-09-24 | The agreement was further amended, extending the maturity date of the revolving line of credit to December 16, 2024. |
| 2024-10-01 | 1,313,555 PIPE warrants converted to shares on cashless basis. |
| 2024-10-09 | Company received a conversion notice for the issuance of approximately 492,800 shares of common stock to a holder of its Convertible Notes as full repayment of the amounts due. |
| 2024-10-28 | NKGen entered into a Securities Purchase Agreement with an accredited investor in connection with a letter agreement with an unsecured convertible promissory note in the principal amount of $369,600. |
| 2024-11-05 | Company conducted a group layoff of 16 employees. |
| 2024-11-20 | Company received a notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1). |
| 2024-11-25 | The Seoul Bankruptcy Court approved a Conditional Investment Agreement for the merger and acquisition of NKMAX Co., Ltd. between NKGen Biotech, Inc. and NKMAX Co., Ltd. |
| 2024-12-06 | Company granted its Chief Executive Officer, Paul Song, and its interim Chief Financial Officer, James Graf, special one time option awards to purchase 2,000,000 and 500,000 shares of the Company's common stock, respectively, under the Company's 2023 Equity Incentive Plan. |
| 2024-12-16 | The agreement was further amended, extending the maturity date of the revolving line of credit to December 16, 2024. |
| 2024-12-31 | Company and an FPA Investor entered into an amendment to the Forward Purchase Agreement whereas the Company and Seller agreed to extend the Valuation Date to December 31, 2025. |
| 2024-12-31 | Company received total proceeds of $4.2 million in exchange for a December 2024 Convertible Note with a principal amount of $4.5 million, 1,500,000 Warrants, and 1,500,000 Consideration Shares. |
| 2025-02-23 | The board of directors (the Board) of NKGen determined to effect a one-for-six (1-for-6) reverse stock split of the Company's common stock, subject to shareholder approval of the Reverse Stock Split Proposal. |
| 2025-02-28 | There were 44,947,588 shares of common stock, $0.0001 par value per share, issued and outstanding. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.